HC Wainwright began coverage on shares of Anixa Biosciences (NASDAQ:ANIX) in a research report report published on Monday, Price Targets.com reports. The brokerage issued a buy rating and a $11.00 price objective on the stock.
Several other analysts also recently issued reports on ANIX. Aegis restated a buy rating on shares of Anixa Biosciences in a research note on Monday, February 15th. Zacks Investment Research upgraded Anixa Biosciences from a strong sell rating to a hold rating in a research note on Monday, March 15th.
ANIX opened at $4.92 on Monday. The business has a fifty day simple moving average of $5.16 and a 200 day simple moving average of $3.78. The company has a market capitalization of $154.64 million, a PE ratio of -10.70 and a beta of 1.58. Anixa Biosciences has a 1 year low of $1.70 and a 1 year high of $8.09.
Several large investors have recently added to or reduced their stakes in ANIX. B. Riley Wealth Management Inc. bought a new stake in shares of Anixa Biosciences during the 4th quarter valued at $37,000. Jane Street Group LLC bought a new stake in shares of Anixa Biosciences during the 3rd quarter valued at $45,000. Bank of New York Mellon Corp lifted its position in shares of Anixa Biosciences by 32.0% during the 4th quarter. Bank of New York Mellon Corp now owns 51,969 shares of the company’s stock valued at $160,000 after acquiring an additional 12,588 shares during the period. Finally, BlackRock Inc. lifted its position in shares of Anixa Biosciences by 8.0% during the 4th quarter. BlackRock Inc. now owns 93,942 shares of the company’s stock valued at $289,000 after acquiring an additional 6,964 shares during the period. Hedge funds and other institutional investors own 7.68% of the company’s stock.
About Anixa Biosciences
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus.
Featured Story: FinTech
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.